Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Profit After Tax (2016 - 2025)

Neurocrine Biosciences' Profit After Tax history spans 16 years, with the latest figure at $153.7 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 49.08% year-over-year to $153.7 million; the TTM value through Dec 2025 reached $478.6 million, up 40.23%, while the annual FY2025 figure was $478.6 million, 40.23% up from the prior year.
  • Profit After Tax reached $153.7 million in Q4 2025 per NBIX's latest filing, down from $209.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $209.5 million in Q3 2025 to a low of -$76.6 million in Q1 2023.
  • Average Profit After Tax over 5 years is $65.7 million, with a median of $66.8 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: skyrocketed 1319.18% in 2022, then tumbled 651.08% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$7.3 million in 2021, then surged by 1319.18% to $89.0 million in 2022, then soared by 65.96% to $147.7 million in 2023, then tumbled by 30.2% to $103.1 million in 2024, then skyrocketed by 49.08% to $153.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Profit After Tax are $153.7 million (Q4 2025), $209.5 million (Q3 2025), and $107.5 million (Q2 2025).